IDH1 and astrocytoma (excluding glioblastoma): The presence of both EGFR amplification and IDH mutation in these high-grade astrocytoma tumors was unusual and raised questions within our clinical team in regards to the tumors’ correct nomenclature, biological behavior, possible syndromic genomic instability, and, ultimately, patient prognosis.